BICO Group AB (publ)
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BICO Group AB (publ) develops and commercializes hardware, software and services that enable and automate life science labs for pharmaceutical, biotech and academic customers worldwide. The company offers lab automation software via its Green Button Go Suite brand; highly purified extracellular matrix (ECM) proteins through the CELLINK brand for tissue engineering, 3D bioprinting, cell culture and drug discovery; single-cell and single-spheroid dispensing technologies via the DispenCell brand; 3D bioprinters under the CELLINK brand for tissue engineering, 3D in vitro models, biomaterial research and drug discovery; automated cell line development workflows through the PFA brand; automated liquid handling solutions via the Biosero brand for drug development, diagnostics and synthetic biology; hybrid microscopes and live-cell imagers under the Nanolive brand; molecular sample mixing and temperature control solutions via the Telescope brand; and precise dispensing automation through the Nordic Nanovector brand. BICO operates in more than 25 countries across North America, Europe and Asia with over 46,000 instruments in the field and more than 10,000 customer publications citing its brands. Founded in 2016 and headquartered in Gothenburg, Sweden, the company maintains two reporting segments of Life Science Solutions and Lab Automation following its Strategy 2.0 launched in September 2024. Recent developments include the divestiture of subsidiaries MatTek Corp and Visikol Inc to Sartorius Lab Holding GmbH for USD 80 million on a cash and debt-free basis, completed in 2025 to focus on core lab automation and selected workflows; a master framework agreement secured by Biosero with a global pharma company for integrated lab automation solutions valued at USD 15.2 million; repurchases of convertible bonds totaling SEK 276 million in February 2025 and additional amounts thereafter to strengthen the balance sheet; an agreement to divest Nanoscribe announced in November 2024; leadership changes such as the appointment of Maria Rankka as Board Chair in September 2025, Lars Risberg as General Counsel in June 2025 and the departure of the COO in May 2025; and the publication of Q3 2025 preliminary figures announcing an impairment charge.
BICO Group AB (publ) (BCCOY) Q1 2026 Earnings Call Transcript
BICO Group AB (publ) (BCCOY) Q4 2025 Earnings Call Transcript
BICO Group AB (publ) (OTCMKTS:CLLKF) Short Interest Update
BICO Group AB (publ) (OTCMKTS:CLLKF) Sees Significant Growth in Short Interest
BICO Group AB (publ) (OTCMKTS:CLLKF) Trading Down 8.1% – Should You Sell?
BICO Group AB (publ) (BCCOY) Q3 2025 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) Q2 2025 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) Q1 2025 Earnings Call Transcript
BICO Group AB (CLLKF) Q4 2024 Earnings Call Transcript
BICO Group AB (CLLKF) Q3 2024 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) Q2 2024 Earnings Call Transcript
The 3 Best 3D Bioprinting Stocks to Buy Now
Lab Instrument Industry Update - New Commercial Entrants
BICO Group AB (publ) (CLLKF) Q1 2024 Earnings Call Transcript
3 3D Printing Stocks With the Potential to Make You an Overnight Millionaire
BICO Group AB (publ) (CLLKF) Q4 2023 Earnings Call Transcript
BICO: Too Many Unknowns
BICO Group AB (publ) (CLLKF) Q2 2023 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) Q1 2023 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) Q4 2022 Earnings Call Transcript